
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex is expected to experience at least 6% sales growth from its combined interventional business, with a solid foundation based on nearly $1 billion in revenue. Potential drivers for continued growth include stronger revenue performance, improved operating margins, and strategic acquisitions that align with higher growth expectations. Additionally, Teleflex's diversified product segments and a geographic focus on the US, which contributes 60% of revenue, position the company favorably for double-digit earnings growth and margin improvements in the future.
Bears say
Teleflex reported disappointing 4Q24 results, which included a significant miss on consensus revenue and EPS guidance for 2025, leading to a 22% decline in share value. The company projected a cautious revenue growth rate of only 1.0-2.0% year-over-year, well below market expectations of 4.5%, primarily due to anticipated challenges in segments such as UroLift and pressures from pricing dynamics in the office setting. Additionally, the firm announced a significant acquisition of Biotronik's Vascular Intervention business for approximately $820 million, although this move could be perceived as risky or dilutive to EPS, further contributing to a negative outlook.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares